Skip to content

Operating Cash Flow at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$220.65M+26.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6.14M+175%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$7.41M+254%
XER
Xeris Biopharma Holdings, Inc.XERS
$9.87M+198%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$51.11M+30.2%
PVL
Palvella TherapeuticsPVLA
-$10.86M-60.5%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Valuation

See full
Market cap$132.59M-87.6%

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's operating cash flow?
Polaryx Therapeutics, Inc. (PLYX) reported operating cash flow of -$2.06M in Q1 2026.
How has Polaryx Therapeutics, Inc. 's operating cash flow changed year-over-year?
Polaryx Therapeutics, Inc. 's operating cash flow decreased by 191.0% year-over-year, from -$709K to -$2.06M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.